MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Marketable securities$247,221K Cash and cashequivalents$129,883K Collaboration receivable$7,000K Other receivables$4,600K Prepaid expenses andother current assets$4,481K Total property andequipment, at cost$53,599K Total current assets$393,185K Property and equipment,net$25,986K Operating leaseright-of-use assets$24,386K Restricted cash$4,954K Other long-termassets$148K Less accumulateddepreciation$27,613K Total assets$448,659K Total liabilities andstockholders' equity$448,659K Total stockholders'equity$233,056K Total liabilities$215,603K Accumulated deficit-$477,214K Accumulated othercomprehensive loss-$3,827K Additional paid-in capital$714,090K Deferred revenue, net ofcurrent$111,332K Total currentliabilities$64,212K Operating leaseliability, net of current$34,794K Defined benefit planliability$5,265K Common stock, 0.0001par value...$7K Current deferredrevenue$29,571K Accrued expenses andother current...$26,694K Current portion ofoperating lease liability$4,397K Accounts payable$3,550K
Balance Sheet
source: myfinsight.com

Monte Rosa Therapeutics, Inc. (GLUE)

Monte Rosa Therapeutics, Inc. (GLUE)